p raf 1  (Santa Cruz Biotechnology)

Journal: Cell Biology and Toxicology

Article Title: RNF115 aggravates tumor progression through regulation of CDK10 degradation in thyroid carcinoma

doi: 10.1007/s10565-024-09845-w

Figure Lengend Snippet: RNF115 facilitates the ubiquitinated degradation of CDK10 and then activates the Raf-1 pathway in thyroid carcinoma (THCA) cells. A Subcellular localization of RNF115 and CDK10 by immunofluorescent staining (scale bar = 20 µm). B The interaction between RNF115 and CDK10 by CoIP assay. C CDK10 ubiquitination was measured by western blotting. D Western blotting shows the expression of RNF115, CDK10, and Raf-1 pathway-related proteins in TPC-1 and SNU-790 cells. Cells were transfected with Ad-RNF115 and/or CDK10. *p < 0.05 and **p < 0.01 vs. Ad-NC + Vector; ##p < 0.01 vs. Ad-RNF115 + Vector

Article Snippet: The primary antibodies used for western blotting were anti-RNF115 (0.4 µg/mL), anti-E-cadherin (1:10,000), anti-N-cadherin (1 µg/mL), anti-CDK10 (1:2,000), anti-SFN (2 µg/mL), anti-MYC (2 µg/mL), anti-p-Raf-1 (1:1,000), anti-Raf-1 (1:2,000), anti-p-MEK1/2 (1;1,000), anti-MEK1/2 (1:1,000), anti-p-ERK1/2 (1:1,000), anti-ERK1/2 (1 µg/mL), anti-CyclinD1 (1 µg/mL), anti-CDK4 (2 µg/mL), anti-Bax (1:100), anti-Cleaved caspase-3 (1:2,000), and anti-β-actin (1:5,000) (Invitrogen, CA, USA).

Techniques: Staining, Co-Immunoprecipitation Assay, Western Blot, Expressing, Transfection, Plasmid Preparation